BDNF plasma levels variations in major depressed patients receiving duloxetine

Michele Fornaro, Andrea Escelsior, Giulio Rocchi, Benedetta Conio, Paola Magioncalda, Valentina Marozzi, Andrea Presta, Bruno Sterlini, Paola Contini, Mario Amore, Pantaleo Fornaro, Matteo Martino

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

It has been frequently reported that brain-derived neurotrophic factor (BDNF) plays an important role in the pathophysiology of major depressive disorder (MDD). Objective of the study was to investigate BDNF levels variations in MDD patients during antidepressant treatment with duloxetine. 30 MDD patients and 32 healthy controls were assessed using Hamilton Depression Scale (HAM-D) and monitored for BDNF plasma levels at baseline, week 6 and week 12 of duloxetine treatment (60 mg/day) and at baseline, respectively. According to early clinical response to duloxetine (defined at week 6 by reduction >50 % of baseline HAM-D score), MDD patients were distinguished in early responders (ER) and early non-responders (ENR), who reached clinical response at week 12. Laboratory analysis showed significant lower baseline BDNF levels among patients compared to controls. During duloxetine treatment, in ENR BDNF levels increased, reaching values not significantly different compared to controls, while in ER BDNF levels remained nearly unchanged. Lower baseline BDNF levels observed in patients possibly confirm an impairment of the NEI stress-adaptation system and neuroplasticity in depression, while BDNF increase and normalization observed only in ENR might suggest differential neurobiological backgrounds in ER vs. ENR within the depressive syndrome.

Original languageEnglish
Pages (from-to)729-734
Number of pages6
JournalNeurological Sciences
Volume36
Issue number5
DOIs
Publication statusPublished - May 1 2015
Externally publishedYes

Fingerprint

Psychiatric Status Rating Scales
Neuronal Plasticity
Brain-Derived Neurotrophic Factor
Major Depressive Disorder
Antidepressive Agents
Young Adult
Outpatients
Depression
Duloxetine Hydrochloride
Depressive Disorder
Therapeutics

Keywords

  • BDNF
  • Depression
  • Duloxetine
  • Neuroendocrine immunity
  • Neuroplasticity

ASJC Scopus subject areas

  • Dermatology
  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Fornaro, M., Escelsior, A., Rocchi, G., Conio, B., Magioncalda, P., Marozzi, V., ... Martino, M. (2015). BDNF plasma levels variations in major depressed patients receiving duloxetine. Neurological Sciences, 36(5), 729-734. https://doi.org/10.1007/s10072-014-2027-7

BDNF plasma levels variations in major depressed patients receiving duloxetine. / Fornaro, Michele; Escelsior, Andrea; Rocchi, Giulio; Conio, Benedetta; Magioncalda, Paola; Marozzi, Valentina; Presta, Andrea; Sterlini, Bruno; Contini, Paola; Amore, Mario; Fornaro, Pantaleo; Martino, Matteo.

In: Neurological Sciences, Vol. 36, No. 5, 01.05.2015, p. 729-734.

Research output: Contribution to journalArticle

Fornaro, M, Escelsior, A, Rocchi, G, Conio, B, Magioncalda, P, Marozzi, V, Presta, A, Sterlini, B, Contini, P, Amore, M, Fornaro, P & Martino, M 2015, 'BDNF plasma levels variations in major depressed patients receiving duloxetine', Neurological Sciences, vol. 36, no. 5, pp. 729-734. https://doi.org/10.1007/s10072-014-2027-7
Fornaro M, Escelsior A, Rocchi G, Conio B, Magioncalda P, Marozzi V et al. BDNF plasma levels variations in major depressed patients receiving duloxetine. Neurological Sciences. 2015 May 1;36(5):729-734. https://doi.org/10.1007/s10072-014-2027-7
Fornaro, Michele ; Escelsior, Andrea ; Rocchi, Giulio ; Conio, Benedetta ; Magioncalda, Paola ; Marozzi, Valentina ; Presta, Andrea ; Sterlini, Bruno ; Contini, Paola ; Amore, Mario ; Fornaro, Pantaleo ; Martino, Matteo. / BDNF plasma levels variations in major depressed patients receiving duloxetine. In: Neurological Sciences. 2015 ; Vol. 36, No. 5. pp. 729-734.
@article{7035940cc381464698459d79c2e3c60a,
title = "BDNF plasma levels variations in major depressed patients receiving duloxetine",
abstract = "It has been frequently reported that brain-derived neurotrophic factor (BDNF) plays an important role in the pathophysiology of major depressive disorder (MDD). Objective of the study was to investigate BDNF levels variations in MDD patients during antidepressant treatment with duloxetine. 30 MDD patients and 32 healthy controls were assessed using Hamilton Depression Scale (HAM-D) and monitored for BDNF plasma levels at baseline, week 6 and week 12 of duloxetine treatment (60 mg/day) and at baseline, respectively. According to early clinical response to duloxetine (defined at week 6 by reduction >50 {\%} of baseline HAM-D score), MDD patients were distinguished in early responders (ER) and early non-responders (ENR), who reached clinical response at week 12. Laboratory analysis showed significant lower baseline BDNF levels among patients compared to controls. During duloxetine treatment, in ENR BDNF levels increased, reaching values not significantly different compared to controls, while in ER BDNF levels remained nearly unchanged. Lower baseline BDNF levels observed in patients possibly confirm an impairment of the NEI stress-adaptation system and neuroplasticity in depression, while BDNF increase and normalization observed only in ENR might suggest differential neurobiological backgrounds in ER vs. ENR within the depressive syndrome.",
keywords = "BDNF, Depression, Duloxetine, Neuroendocrine immunity, Neuroplasticity",
author = "Michele Fornaro and Andrea Escelsior and Giulio Rocchi and Benedetta Conio and Paola Magioncalda and Valentina Marozzi and Andrea Presta and Bruno Sterlini and Paola Contini and Mario Amore and Pantaleo Fornaro and Matteo Martino",
year = "2015",
month = "5",
day = "1",
doi = "10.1007/s10072-014-2027-7",
language = "English",
volume = "36",
pages = "729--734",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia",
number = "5",

}

TY - JOUR

T1 - BDNF plasma levels variations in major depressed patients receiving duloxetine

AU - Fornaro, Michele

AU - Escelsior, Andrea

AU - Rocchi, Giulio

AU - Conio, Benedetta

AU - Magioncalda, Paola

AU - Marozzi, Valentina

AU - Presta, Andrea

AU - Sterlini, Bruno

AU - Contini, Paola

AU - Amore, Mario

AU - Fornaro, Pantaleo

AU - Martino, Matteo

PY - 2015/5/1

Y1 - 2015/5/1

N2 - It has been frequently reported that brain-derived neurotrophic factor (BDNF) plays an important role in the pathophysiology of major depressive disorder (MDD). Objective of the study was to investigate BDNF levels variations in MDD patients during antidepressant treatment with duloxetine. 30 MDD patients and 32 healthy controls were assessed using Hamilton Depression Scale (HAM-D) and monitored for BDNF plasma levels at baseline, week 6 and week 12 of duloxetine treatment (60 mg/day) and at baseline, respectively. According to early clinical response to duloxetine (defined at week 6 by reduction >50 % of baseline HAM-D score), MDD patients were distinguished in early responders (ER) and early non-responders (ENR), who reached clinical response at week 12. Laboratory analysis showed significant lower baseline BDNF levels among patients compared to controls. During duloxetine treatment, in ENR BDNF levels increased, reaching values not significantly different compared to controls, while in ER BDNF levels remained nearly unchanged. Lower baseline BDNF levels observed in patients possibly confirm an impairment of the NEI stress-adaptation system and neuroplasticity in depression, while BDNF increase and normalization observed only in ENR might suggest differential neurobiological backgrounds in ER vs. ENR within the depressive syndrome.

AB - It has been frequently reported that brain-derived neurotrophic factor (BDNF) plays an important role in the pathophysiology of major depressive disorder (MDD). Objective of the study was to investigate BDNF levels variations in MDD patients during antidepressant treatment with duloxetine. 30 MDD patients and 32 healthy controls were assessed using Hamilton Depression Scale (HAM-D) and monitored for BDNF plasma levels at baseline, week 6 and week 12 of duloxetine treatment (60 mg/day) and at baseline, respectively. According to early clinical response to duloxetine (defined at week 6 by reduction >50 % of baseline HAM-D score), MDD patients were distinguished in early responders (ER) and early non-responders (ENR), who reached clinical response at week 12. Laboratory analysis showed significant lower baseline BDNF levels among patients compared to controls. During duloxetine treatment, in ENR BDNF levels increased, reaching values not significantly different compared to controls, while in ER BDNF levels remained nearly unchanged. Lower baseline BDNF levels observed in patients possibly confirm an impairment of the NEI stress-adaptation system and neuroplasticity in depression, while BDNF increase and normalization observed only in ENR might suggest differential neurobiological backgrounds in ER vs. ENR within the depressive syndrome.

KW - BDNF

KW - Depression

KW - Duloxetine

KW - Neuroendocrine immunity

KW - Neuroplasticity

UR - http://www.scopus.com/inward/record.url?scp=84939940786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939940786&partnerID=8YFLogxK

U2 - 10.1007/s10072-014-2027-7

DO - 10.1007/s10072-014-2027-7

M3 - Article

C2 - 25501804

AN - SCOPUS:84939940786

VL - 36

SP - 729

EP - 734

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - 5

ER -